Business
AIM Admission & First Day of Dealings
AIM Admission & First Day of Dealings.
About this update from Verici Dx Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 0201E\n Verici Dx PLC\n 03 November 2020\n \n \n \n \n Not for release, publication or distribution, directly or indirectly, in whole or in part, in, into or within the United States, Australia, Canada, Hong Kong, Japan, New Zealand, the Republic of South Africa or any other jurisdiction where it is unlawful to distribute this announcement.\n \n \n \n \n \n \n \n 3 November 2020\n \n Verici Dx plc\n \n \n (\"Verici Dx\" or the \"Company\") \n \n \n \n \n Admission to trading on AIM\n & First Day of Dealings\n \n \n Capitalised terms used in this announcement shall, unless the context provides otherwise, have the same meaning as defined in the Admission Document.\n \n \n Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that admission to trading on AIM (\"Admission\") will take place and dealings will commence at 8.00 a.m. today under the ticker VRCI and ISIN GB00BM8HZD43.\n \n \n The Company's Admission Document is\n available here: \n \n https://vericidx.com/investors/\n \n \n \n \n Key Highlights:\n \n · Successful Fundraising for gross proceeds of £14.5 million\n \n · The Fundraising was significantly oversubscribed across all components, including the Placing (approximately £12.06 million), the Subscription (approximately £2.06 million) and the Restricted Offer (approximately £0.38 million)\n \n · Market capitalisation of approximately £28.35 million on Admission\n \n · Enlarged Share Capital on Admission of 141,747,816 Ordinary Shares\n \n · The 72,500,000 New Ordinary Shares represent 51.2 per cent. of the Enlarged Share Capital\n \n · N+1 Singer acted as Sole Bookrunner in relation to the Placing and is acting as the Company's Nominated Adviser and Broker from Admission\n \n About Verici Dx\n \n The Company is an immuno-diagnostics development company, initially focussed on the kidney transplantation market. The Company's kidney transplant assays will use advanced next-generation sequencing that may define a personalised risk profile of each patient over the course of their transplant journey, and may also detect injury in advance of currently available clinical tests.\n \n The Company develops tests to understand how a patient is likely to, and may be, responding ...